Bioequivalence Analysis of Empagliflozin and Linagliptin in Human Plasma Using LC-MS/MS: Validation and Stability Studies
کلمات کلیدی:
Dariush Omidfar, Ahad Sheikhlooچکیده
This study presents a comprehensive bioequivalence analysis of Empagliflozin and Linagliptin (10/5 mg) in human plasma, utilizing a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology. The method was validated according to EMEA and ICH M10 guidelines to ensure specificity, precision, accuracy, matrix effect evaluation, and stability under various conditions. Calibration curves demonstrated excellent linearity over the concentration range of 0.5–320 ng/mL for both compounds. The method's lower limit of quantification (LLOQ) was established at 0.5 ng/mL with a signal-to-noise ratio exceeding 10, confirming the sensitivity of the assay.
Precision studies yielded within-run and between-run %RSD values within the acceptable limits, indicating high repeatability and reliability of the measurements. Matrix effects, assessed across six plasma sources, showed minimal interference, ensuring robustness of the results. Short-term and freeze-thaw stability assessments revealed deviations below ±10%, underscoring the suitability of the method for bioanalytical applications.
Plasma samples collected from healthy volunteers were analyzed to determine pharmacokinetic parameters, supporting the bioequivalence of test and reference formulations. This validated method enables accurate quantification of Empagliflozin and Linagliptin in clinical studies and reinforces its utility for therapeutic drug monitoring and bioequivalence assessments.
دانلودها
مراجع
- Abdel-Ghany, M. F., and Abdel-Aziz, O. (2020). Pharmaceutical Analysis of Linagliptin and Empagliflozin using LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, 180, 113012.
- Abbas Moussa, B., Mahrouse, M. A., and Fawzy, M. G. (2019). A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. *Journal of Pharmaceutical and Biomedical Analysis*, 163, 153-161.
- Food and Drug Administration. (2015). Clinical Pharmacology and Biopharmaceutics Review(s): NDA 206073. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206073Orig1s000ClinPharmR.pdf
- Food and Drug Administration. (2020). Clinical Pharmacology and Biopharmaceutics Review(s): NDA 212614. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212614Orig1s000ClinPharmR.pdf
- Said, R., Arafat, B., and Arafat, T. (2024). A Bioanalytical Method Using High-Performance Liquid Chromatography-Mass Spectrometry for Determining Empagliflozin and Linagliptin in Human Plasma: Application in Bioequivalence Pharmacokinetic Study. *Current Pharmaceutical Analysis*, 20(9).
- Xue, Y. J., Akinsanya, J. B., Liu, J., and Unger, S. E. (2006). A simplified protein precipitation/mixed-mode cation-exchange solid-phase extraction, followed by high-speed liquid chromatography/mass spectrometry, for the determination of a basic drug in human plasma. *Rapid Communications in Mass Spectrometry*, 20(18), 2660-2668.
